Volume 35, No 11, Nov 2025

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 35 Issue 11, November 2025: 790-791

RESEARCH HIGHLIGHTS

Selective CDK4 inhibition holds promise for breast cancer

Manuel Beltrán-Visiedo¹ , Rebecca M. Shulman^2,* , Lorenzo Galluzzi^1,*

¹Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA
²Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Correspondence: Rebecca M. Shulman(rebecca.shulman@fccc.edu)Lorenzo Galluzzi(deadoc80@gmail.com)

Although CDK4/6 inhibitors have revolutionized the management of patients with locally advanced/metastatic HR+HER2− breast cancer, hematological side effects, notably neutropenia, have been challenging to circumvent. A highly selective CDK4 inhibitor has recently been shown to cause limited hematological toxicity in preclinical breast cancer models, hence enabling dose escalation in support of superior tumor control.

https://doi.org/10.1038/s41422-025-01117-4

FULL TEXT | PDF

Browse 211